Pulmonx will use ERS2026 to spotlight its Zephyr Valves BLVR therapy, making severe COPD and emphysema a central focus. The company is inviting clinicians to Bo

Pulmonx will use ERS2026 to spotlight its Zephyr Valves BLVR therapy, making severe COPD and emphysema a central focus. The company is inviting clinicians to Booth H.01 and is backing the push with new COPD data tools for patient management.